Kentucky’s Patent of the Month – October 2020
Worldwide, one in five people will develop cancer and one in six people will fall victims to it. Cancer is constantly mutating and evolving, so making specific diagnosis is hard to do; but we are evolving with it. Huang-Ge Zhang, with the University of Louisville (UofL), has developed a new revolutionary system for the diagnosis and prognosis of cancer. The method involves the collection and isolation of nanovesicles (i.e. tiny sacs released by cells that carry chemical messages – our body’s natural delivery vehicle) from a patient’s biological sample. It’s like the nanovesicles are the operating board between us and our own cells. The UofL is making a connection and listening to what our cells have to say.
We are multicellular organisms and rely heavily on intercellular communications. An important source of this communication is extracellular microvesicles (EVs), those little sacs we mentioned earlier. Recent research has shown that understanding the number and type of EVs in a cell can improve cancer diagnostic methods. But, there are many different types of EVs, so it’s difficult to determine which EVs are the most abundant in a patient sample. Exomes (part of the human genome) are the main group of EVs in a body; however, it’s hard to characterize the different exomes using current isolation methods. In addition, the data collected from in vitro analysis methods may not fully represent what happens in the body.
The method developed by UofL includes studying nanovesicles from a biological sample, such as blood or urine. Exomes are then isolated by targeting nanovesicles of certain size and charge requirements. The UofL then determines the amount of nanovesicles in the sample along with other measures, such as lipids, peptides, and RNA molecules. They use this information to assess the likelihood of different cancers, by comparing this sample to a control. , and to develop tailored treatment plans .
Are you developing a new medical technique? Did you know your R&D experiments could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.